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In this modern era of management of various cardiovascular
disorders, surgical therapy has virtually always preceded the
development of percutaneous techniques. This has been the
case with myocardial revascularization (aortocoronary by-
pass surgery vs. angioplasty), procedures for mitral stenosis
(surgical commissurotomy vs. balloon valvuloplasty) as well
as for the management of certain congenital heart defects
such as patent ductus arteriosus or atrial septal defect
(surgical closure vs. percutaneous device closure). In each
instance, surgery has proven the value of these procedures;
subsequently, the percutaneous techniques have attempted
to match the surgical results. With all of these techniques,
there is obviously a learning curve involved in both the
surgical and interventional procedures.
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This same sequence has now occurred in the management
of hypertrophic obstructive cardiomyopathy (HOCM). Sur-
gical myectomy for severely symptomatic patients with
subaortic obstructive hypertrophic cardiomyopathy (HCM)
has been performed for some 40 years (1–5), and several
centers have been continuously involved in this type of
surgery for this entire period of time (3–9). Even medical
therapy followed the surgical approach in the management
of HOCM (10). Subsequently, atrioventricular (AV) se-
quential pacing has been used to reduce the severity of the
obstruction in HOCM. Although initial results suggested
that pacing was a panacea for the management of these
patients (11), randomized controlled trials provided less
favorable results, in that there was incomplete gradient
reduction, and objective evidence of symptomatic improve-
ment was lacking (12–14). One study (15) demonstrated
that surgery provided greater benefit than pacemaker ther-
apy.
In 1995, Sigwart (16) first described the effect of occlud-
ing a septal perforator artery with ethanol on the pressure
gradient in HOCM. The procedure, which results in a
localized septal infarction, was referred to as nonsurgical
septal reduction therapy (NSRT). Subsequently, two Ger-
man centers have reported extensive experience in many
hundreds of patients (17,18). Seggewiss and associates (17)
have referred to the procedure as percutaneous transluminal
septal myocardial ablation (PTSMA), while Gietzen and
associates (18) have termed the procedure transcoronary
ablation of septal hypertrophy (TASH). The largest North
American experience with septal ethanol ablation has been
that of Spencer and colleagues from Baylor College of
Medicine in Houston (19).
Evidence has been accumulating that the amount of
ethanol used and the number of septal perforator arteries
ablated determine the height of the creatine kinase (CK)
rise (the size of the induced infarction), the degree of acute
gradient reduction, the incidence of complete heart block
and mortality (17–19). The introduction of myocardial
contrast echocardiography by Faber et al. (20) allows for the
correct identification of the appropriate septal perforator to
be occluded and the avoidance of occluding septal perfora-
tors that supply distant areas of the myocardium such as the
papillary muscles or the free wall of the left or right
ventricle. The observation that there is further gradient
reduction in the year following the procedure (17) has led to
a less aggressive approach in terms of the amount of ethanol
used and the number of vessels ablated during the proce-
dure, with a resultant decrease in the incidence of heart
block (9,17–19).
In this issue of the Journal, Nagueh et al. (9) report on the
first attempt to compare the results of ethanol septal
reduction therapy with surgical myectomy in the treatment
of HOCM. Although several centers with extensive surgical
experience are also now performing alcohol ablation proce-
dures (21,22), no one center has extensive experience with
both techniques. Thus, to compare the results of the two
techniques, the investigators have compared the results of
the Baylor Group with the largest North American experi-
ence using alcohol ablation, with age and gradient (but not
gender)-matched patients from the surgical experience at
the Mayo Clinic (9). At baseline the two groups were well
matched as to age, symptomatic status, severity of obstruc-
tion and related mitral regurgitation and the types of
medication. Both groups contained a significant number of
patients with permanent pacemakers implanted for the
therapy of HOCM (not for heart block). The fact that so
many of these patients with implanted pacemakers subse-
quently required a second intervention speaks for itself.
The results in the two groups at one year of follow-up
were remarkably similar in terms of mortality, gradient
reduction, symptomatic benefit, objective measures of im-
proved exercise tolerance, and echocardiographic parame-
ters, including the degree of mitral regurgitation (9). After
NSRT, the incidence of pacemaker implantation for com-
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plete heart block was significantly higher than in the surgical
cohort (22% vs. 2%). However, seven of nine pacemakers in
the NSRT group were implanted prior to the procedural
modifications previously mentioned, which involve the use
of myocardial contrast echocardiography to correctly iden-
tify the target vessel, and to bring about slower injections
and smaller amounts of ethanol, and acceptance of a higher
residual gradient immediately following the procedure,
knowing that the gradient progressively lessens over the first
year of follow-up (17).
One NSRT patient had an implantable cardioverter-
defibrillator (ICD) implanted for sustained ventricular
tachycardia, following the procedure, whereas four surgical
patients had an ICD implanted postoperatively; one for
preoperative ventricular fibrillation and three for ventricular
arrhythmias and risk factor profiles.
In the surgical group, there was a higher postoperative
incidence of mild (10 patients) or moderate (1 patient)
aortic regurgitation and a greater use of beta-blockers and
calcium blockers that was said to be institution-specific and
not related to gradient reduction. Postoperative atrial fibril-
lation occurred only in the surgical group, but all patients
were discharged in normal sinus rhythm.
COMMENTS
It is important to stress that all patients in this study (9)
suffered from subaortic obstructive HCM and not midven-
tricular obstruction. The severity of the subaortic obstruc-
tion and the concomitant mitral regurgitation are directly
related to the severity of the mitral leaflet systolic anterior
motion (23–26). Previous surgical (22–26) and ablation
(16–19,22) studies have demonstrated that thinning of the
septum and widening of the outflow tract are associated
with a decrease or abolition of systolic anterior motion, the
pressure gradient and mitral regurgitation. In approximately
20% of patients, there is a structural abnormality of the
mitral valve such as anomalous papillary muscle or mitral
valve prolapse, which can cause mitral regurgitation (23)
and which is often anteriorly or centrally directed into the
left atrium, allowing distinction from the posteriorly di-
rected mitral regurgitation, related to systolic anterior mo-
tion (25,26). Patients with structural abnormalities of the
mitral valve or with midventricular obstruction were ex-
cluded from the present study. Patients with latent or
provocable obstruction were also excluded because the
techniques to provoke the obstruction in the two institu-
tions were not comparable.
CONTRIBUTIONS OF THE STUDY
The essential contribution of this study (9) is the compara-
bility of the results of NSRT and myectomy surgery for the
treatment of severely symptomatic medically refractory sub-
aortic obstructive HCM, when each procedure is carried out
by experienced operators.
COMPLICATIONS
Nonsurgical septal reduction therapy. CORONARY AR-
TERY DISSECTION. Several major complications of NSRT
were encountered in the Nagueh et al. study. There was one
death due to coronary artery dissection that occurred with
the use of a standard guide wire. Subsequently, the operators
used a high-torque, floppy wire in an attempt to avoid this
complication.
VENTRICULAR CONDUCTION DEFECTS AND HEART BLOCK.
The occurrence of ventricular conduction defects with
alcohol ablation (especially right bundle branch block) and
complete heart block has been well recognized and requires
the introduction of a temporary pacemaker wire prior to the
procedure (16–19). With a refined and less aggressive
technique, the incidence of dense heart block has signifi-
cantly lessened but remains significant and is greater than
that caused by myectomy surgery (9).
VENTRICULAR ARRHYTHMIAS. The third complication of
alcohol ablation reported in this study was the occurrence of
sustained ventricular tachycardia requiring ICD implanta-
tion. Several investigators have expressed concern about the
possibility of inducing ventricular arrhythmias by causing a
myocardial infarction in HCM patients, who are known to
already have an arrhythmogenic milieu (27). At present, the
risk of ventricular arrhythmias post-NSRT is unclear.
UNWANTED MYOCARDIAL INFARCTION. A fourth and
dreaded complication of alcohol ablation, which did not
occur in this study, is the occurrence of unwanted myocar-
dial infarction distant from the planned septal infarction.
An anterior infarction may occur if alcohol leaks back into
the left anterior descending coronary artery, resulting in
occlusion of that vessel (28). This is a well-recognized
complication and has resulted in the death of some patients.
Less well recognized is the occurrence of left ventricular
free-wall or papillary muscle infarction, or right ventricular
free-wall infarction, which can occur when a septal perfo-
rating artery supplies regions of the heart distant from the
septum. Such vessels may be recognized and ethanol injec-
tion avoided by the use of myocardial contrast echocardi-
ography (20). Mortality can occur from any of these
complications of NSRT.
Surgery. VENTRICULAR CONDUCTION DEFECTS AND
HEART BLOCK. Whereas the myotomy operation for
HOCM produced a left anterior hemi-block in the majority
of patients (4), myectomy surgery produces left bundle
branch block in the majority and rarely causes complete
heart block (7,8). In this series (9), 1 in 41 patients (2.4%)
required a pacemaker for heart block, which is similar to
other large surgical series (8). Thus, surgery has an advan-
tage over NSRT in this respect.
AORTIC REGURGITATION. The incidence of postprocedure
aortic regurgitation was greater (27%) in the surgical group
than in the NSRT group (7%). We have previously reported
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on the occurrence of aortic regurgitation following myec-
tomy (29). It is almost always mild and has not been a
clinical problem in 333 consecutive cases operated upon in
this center over the past 23 years (8). We have speculated
that the aortic regurgitation may result from the surgical
removal of the immediate subaortic muscle, which may act
as a support for the aortic valve. It is not due to valve
damage at the time of surgery. Often, NSRT leaves a ridge
of noninfarcted muscle in the immediate subaortic area,
possibly explaining the reduced incidence of aortic regurgi-
tation.
POSTOPERATIVE ATRIAL FIBRILLATION. Transient postop-
erative atrial fibrillation occurred in 20% of the surgical
patients and in none of the NSRT patients. All surgical
patients, however, were discharged in normal sinus rhythm.
Atrial fibrillation in HCM is almost always related to left
atrial enlargement, which is most frequently encountered in
HOCM, possibly because of the concomitant mitral regur-
gitation (23–26). Both surgery (7,8) and NSRT (17–19)
have been shown to reduce left atrial size postprocedure,
which represents good atrial antiarrhythmic therapy for
these patients. In our surgical series, left atrial size and the
occurrence of early postoperative atrial fibrillation was a
predictor of late postoperative atrial fibrillation (8).
Other complications that have previously been reported
following myectomy and that did not occur in this series are
surgically induced ventricular septal defect or mitral regur-
gitation (7,8).
Study limitations. The investigators have drawn attention
to the fact that their study (9) was not a randomized trial
and that the results are not generally applicable as both
centers are experienced and expert in their respective pro-
cedures (9). The fact that no one center in the world today
is equally experienced in both techniques makes randomized
trials problematic. However, experienced surgical centers
with moderate experience in alcohol ablation may represent
the best opportunity for randomized studies in the future.
Additional considerations. The investigators (9) report
only the follow-up data after one year. There are some very
careful studies following ethanol ablation that indicate an
acute reduction but not abolition of the resting and pro-
voked gradient at the time of the procedure, with further
progressive reduction in both resting and provoked gradi-
ents up to one year following the procedure (17). In our
experience, surgery usually produces immediate abolition of
the resting and provoked pressure gradient at the time of the
procedure (4,7,8).
In the Nagueh et al. study, more than 40% in both groups
had a permanent pacemaker at follow-up and 81% of the
surgical patients and 30% of the NSRT patients were on
negative inotropic drug therapy. Thus, the observed results
of the procedures themselves are compromised by these
additional treatment modalities, which also have the poten-
tial to reduce the obstruction. In addition, no information is
provided on whether or not provocable gradients were
present in either group at follow-up. Provocable gradients
are often still present one year after ablation therapy (17). In
a surgical series, the best clinical results were obtained when
there was no resting or provocable gradient postoperatively
in the absence of pacemaker or drug therapy (4,7,8).
Nagueh and colleagues (9) have attributed the improved
exercise performance following these procedures to a de-
crease in mitral regurgitation and improved diastolic func-
tion. Because the investigators report a high incidence of
presyncope and syncope (presumably with exertion) before
the procedures, and a markedly reduced incidence following
the procedures, it would seem that relief of the outflow
obstruction also played a significant role in explaining the
improved exercise performance and relief of symptoms.
There have been reports of performing ethanol ablation
following unsuccessful myectomy (17) and myectomy fol-
lowing unsuccessful ethanol ablation. Because myectomy
almost always causes left bundle branch block and ethanol
ablation causes right bundle branch block in 60% of cases
(17,18), one would expect a very high incidence of complete
heart block if both procedures were required in any given
patient.
Advantages of ethanol ablation. These advantages in-
clude:
1) avoidance of cardiopulmonary bypass with attendant
risks, especially in elderly patients;
2) shorter hospital stay in this series, although two large
German series reported longer hospital stays to observe
for delayed heart block (17,18);
3) shorter recovery time; and
4) less expense.
Advantages of myectomy surgery. These advantages in-
clude:
1) more immediate and complete relief of resting and
provoked obstruction and concomitant mitral regurgita-
tion;
2) smaller incidence of complete heart block, requiring
pacemaker;
3) excellent long-term results (20 to 30 years vs. 5 years
for ablation);
4) no risk of coronary dissection or unwanted myocardial
infarction;
5) no evidence in long-term studies that myectomy is
arrhythmogenic;
6) ability to deal with concomitant problems such as mid-
ventricular obstruction, constricting muscle bridges over
the left anterior descending coronary artery, aortocoro-
nary bypass surgery, right ventricular outflow obstruc-
tion, mitral valve repair or replacement for additional
valvular problems; and
7) in a small but significant percent of patients, it is not
possible to carry out NSRT for technical reasons, and
NSRT may be less effective in younger patients with
thicker septa (30) and in other specific circumstances.
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Summary. This report (9), comparing the one-year
follow-up results of septal ethanol ablation by the Baylor
Group and the surgical myectomy results at the Mayo
Clinic in the management of subaortic obstructive HCM,
indicates that appropriate basal septal thinning by either
technique provides comparable results. Although a nonran-
domized study and not generally applicable because of the
specialized experience with one technique in each center,
the Nagueh et al. (9) study should provide the groundwork
for future randomized trials. Such trials are most likely to
occur in a number of surgical centers that have extensive
experience with myectomy and that now have several years
of experience with ethanol ablation. Finally, one cannot help
but comment that there no longer appears to be any debate
about the significance of the subaortic pressure gradient in
HOCM. Now the debate is whether to ablate or operate!
Reprint requests and correspondence: Dr. E. Douglas Wigle,
12-217 Eaton North, Toronto General Hospital, 200 Elizabeth
Street, Toronto, Ontario, Canada M5G 2C4.
REFERENCES
1. Cleland WP. The surgical management of obstructive cardiomyopa-
thy. J Cardiovasc Surg (Torino) 1963;4:489–91.
2. Morrow AG, Brockenbrough EC. Surgical treatment of idiopathic
hypertrophic subaortic stenosis. Technic and hemodynamic results of
subaortic ventriculomyotomy. Ann Surg 1961;154:181–9.
3. Kirklin JW, Ellis FH Jr. Surgical relief of diffuse subvalvular aortic
stenosis. Circulation 1961;24:739–42.
4. Wigle ED, Chrysohou A, Bigelow W. Results of ventriculomyotomy
in muscular subaortic stenosis. Am J Cardiol 1963;11:572–86.
5. Schulte HD, Bircks WH, Loesse B, Godehardt EAJ, Schwartzkopff
B. Prognosis of patients with hypertrophic obstructive cardiomyopathy
after transaortic myectomy. J Thorac Cardiovasc Surg 1993;106:709–
17.
6. Beahrs MM, Tajik AJ, Seward JB, et al. Hypertrophic obstructive
cardiomyopathy: 10–21-year follow-up after partial septal myectomy.
Am J Cardiol 1983;51:1160–6.
7. Williams WG, Wigle ED, Rakowski H, Smallhorn J, LeBlanc J,
Trusler GA. Results of surgery for hypertrophic obstructive cardiomy-
opathy. Circulation 1987;76:104–8.
8. Choi R, Woo A, Wigle ED, Rakowski P, Williams WG, Rakowski
H. Long-term clinical follow-up of surgical myectomy for hypertro-
phic obstructive cardiomyopathy (abstr). Circulation 2000;102:II-694.
9. Nagueh SF, Ommen SR, Lakkis NM, et al. Comparison of ethanol
septal reduction therapy with surgical myectomy for the treatment of
hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 2001;38:
1701–6.
10. Wigle ED, Adelman AG, Felderhof CH. Medical and surgical
treatment of the cardiomyopathies. Circ Res 1974;34:II-196–207.
11. Fananapazir L, Epstein ND, Curiel RV, Panza JA, Tripodi D,
McAreavery D. Long-term results of dual-chamber (DDD) pacing in
obstructive hypertrophic cardiomyopathy: evidence for progressive
symptomatic and hemodynamic improvement and reduction of left
ventricular hypertrophy. Circulation 1994;90:2731–42.
12. Nishimura RA, Trusty JM, Hayes DL, et al. Dual-chamber pacing for
patients with hypertrophic cardiomyopathy: a prospective randomized
double-blind crossover trial. J Am Coll Cardiol 1997;29:435–41.
13. Kappenberger L, Linde C, Daubert C, et al., for the PIC study group.
Pacing in hypertrophic obstructive cardiomyopathy. Eur Heart J
1997;18:1249–56.
14. Maron B, Nishimura R, McKenna WJ, Rakowski H, Josephson ME,
Kieval RS. Assessment of permanent dual-chamber pacing as a
treatment for drug-refractory symptomatic patients with obstructive
hypertrophic cardiomyopathy (M-PATHY trial). Circulation 1999;22:
2927–33.
15. Ommen SR, Nishimura RA, Squires RW, Schaff HV, Daneilson GK,
Tajik AJ. Comparison of dual-chamber pacing versus septal myectomy
for the treatment of patients with hypertrophic obstructive cardiomy-
opathy: a comparison of objective hemodynamic and exercise end
points. J Am Coll Cardiol 1999;34:191–6.
16. Sigwart U. Non-surgical myocardial reduction for hypertrophic ob-
structive cardiomyopathy. Lancet 1995;346:211–4.
17. Seggewiss H, Faber L, Gleichmann U. Percutaneous transluminal
septal ablation in hypertrophic obstructive cardiomyopathy. Thorac
Cardiovasc Surg 1999;47:94–100.
18. Gietzen FH, Leuner CJ, Raute-Kreinsen U, et al. Acute and long-
term results after transcoronary ablation of septal hypertrophy
(TASH). Catheter interventional treatment for hypertrophic obstruc-
tive cardiomyopathy. Eur Heart J 1999;20:1342–54.
19. Lakkis NM, Nagueh SF, Dunn JK, Killip D, Spencer WH. Nonsur-
gical septal reduction therapy for hypertrophic obstructive cardiomy-
opathy: one-year follow-up. J Am Coll Cardiol 2000;36:852–5.
20. Faber L, Seggewiss H, Gleichmann U. Percutaneous transluminal
septal myocardial ablation in hypertrophic obstructive cardiomyopathy.
Results with respect to intraprocedural myocardial contrast echocardi-
ography. Circulation 1998;98:2415–21.
21. Woo A, Rakowski H, Ross J, et al. Percutaneous transluminal septal
myocardial ablation for hypertrophic obstructive cardiomyopathy:
initial results and clarification of mechanism of benefit (abstr). Can
J Cardiol 1999;15:174D.
22. Sitges M, Shiota T, Lever HM, et al. Evaluation of left ventricular
outflow tract area after sepal reduction in hypertrophic obstructive
cardiomyopathy: a real-time three-dimensional echocardiographic
study (abstr). J Am Coll Cardiol 2001;37 Suppl A:200A.
23. Wigle ED, Sasson Z, Henderson MA, et al. Hypertrophic cardiomy-
opathy: the importance of the site and the event of hypertrophy: a
review. Prog Cardiovasc Dis 1985;28:1–83.
24. Wigle ED, Rakowski H, Kimball BP, Williams WG. Hypertrophic
cardiomyopathy. Clinical spectrum and treatment. Circulation 1995;
92:1680–92.
25. Grigg LE, Wigle ED, Williams WG, Danie LB, Rakowski H.
Transesophageal Doppler echocardiography in obstructive hypertro-
phic cardiomyopathy: clarification of pathophysiology and importance
in intraoperative decision making. J Am Coll Cardiol 1992;20:42–52.
26. Yu EHC, Omran AS, Wigle ED, Williams WG, Siu SC, Rakowski
H. Mitral regurgitation in hypertrophic obstructive cardiomyopathy:
relationship to obstruction and relief with myectomy. J Am Coll
Cardiol 2000;36:2219–25.
27. Spirito P, Maron BJ. Perspectives on the role of new treatment
strategies in hypertrophic obstructive cardiomyopathy. J Am Coll
Cardiol 1999;33:1071–5.
28. Ruzyllo W, Chojnowska L, Demkow M, et al. Left ventricular outflow
tract gradient decrease with non-surgical myocardial reduction im-
proves exercise capacity in patients with hypertrophic obstructive
cardiomyopathy. Eur Heart J 2000;21:770–7.
29. Sasson Z, Prieur T, Skrobik Y, et al. Aortic regurgitation: a common
complication after surgery for hypertrophic obstructive cardiomyopa-
thy. J Am Coll Cardiol 1989;13:63–7.
30. Seggewiss H, Faber L, Ziemssen P, et al. Age related acute results of
percutaneous septal ablation in hypertrophic obstructive cardiomyop-
athy (abstr). J Am Coll Cardiol 2000;35 Suppl A:188A.
1710 Wigle et al. JACC Vol. 38, No. 6, 2001
Editorial Comment November 15, 2001:1707–10
